NTEK Nothing else matters!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Happy Easter to all as well! Simps you are one of the original good guys here! Good to know you still keep the watch, we have learned a lot over the years! BIEL just needs to make it right!
Straws of hope? How about facts are facts? My good friend Tantalos has seen these before and he knows the science of PEMF therapy does not lie. Take a look at my Wife's since deceased dog Devon. Had a huge tumor removed and the vet basically cut him halfway around. The use of the ActiPatch was amazing showing where it was applied near the top of the incision. After a few weeks of mending the area with the Actipatch was far superior healing where the fur had actually grown back over the scar/wound. The pictures are not for the squeamish but meant to show the power of the patch! Don't be left with the short straw when it comes to wearing or not wearing the ActiPatch!
Agree! When a company can control some of its cost structure it can sustain inflationary adjustments and in good times boom in profits. Kelly is in the know on this and it has much more impact than we think! Great post!
Excellent point Tantalos! You and I know a "few" other companies who fall under this same quiet perspective as things are sorted out with these changes made throughout the OTC Exchange! Patience is key but 2022 is shaping up to be a very interesting "BIEL" year!
Nope you don't need to say more!
Just HAPPY NEW YEAR!
Totally agree Hawk, say what you mean and mean what you say! They need to put their money where their mouth is and prove that at the core it's all about pain and healing and effectiveness.
Who cares about what day and what number listed on Amazon, just crumbs and babble. How about closing in on the big fish like Opioids and where BIEL is eating away at the heart of the monster!
https://www.reuters.com/business/judge-tosses-deal-shielding-purdues-sackler-family-opioid-claims-2021-12-17/
From SAI....
I apologize but that item is not available yet
Stephanie Oakes
Customer Service
Surgical Appliance Industries (SAI)
TRUFORM
My Amazon link is down. I think you publish the ranking usually for the KT patch? Typically its towards the top of the list of 4,000 items. Can you provide an update?
Just know its climbing!
There is all the proof I needed to understand the facts! Thank you for validating my DD!
ddls Saturday, 07/24/21 11:21:03 AM
Re: post# 271130 0
Post #
271132
of 271140
Wrong, retail sales are stagnant.
Everything I say and write is my opinion and my opinion only. Do your own due diligence when investing
Opioid epidemic forcing drug companies to pay historic amount of money to bring much-needed treatment and recovery. Why not use electrocuticals? Times are a changing.
https://www.npr.org/2021/07/21/1018881195/state-attorneys-general-26-billion-opioid-settlement
Spot on Tantalos! That would forever set the precedence and rise in market cap would reflect the REAL valued share price!
Attention ddls (lower case), capture the correct data points, KT WAVE /ActiPatch is climbing through the AMAZON jungle! Piney is spot on! Getting to know the future of pain treatment is so hard for some to grasp!
Oops ! Another avenue/revenue seller of the ActiPatch. Imagine the changes at BIEL headquarters coming with these revenue streams!
https://www.hammacher.com/product/electromagnetic-knee-pain-reliever?source=PRODSEM&cm_ven=Criteo&cm_cat=Retargeting&cm_pla=PPC&cm_ite=Dynamic|96866
Absolutely Hawk the transition to the new branding is key to success. I have not seen my Dr. for a few months but plan on bringing in the product name change information on my next visit! You da man!
Right! 15 years ago wasn't much to talk about in sales and today and tomorrow probably pretty slow for a holiday weekend but boy I sure like where the future sales are headed! If anyone has been here for 15 years then you know our time has come! ; )
Makes no sense to keep looking in the rear view mirror. There is a multitude of things in the hopper looking forward! I will speak to that personally with lets just say "Special Interface".
Still a BIELiever!
Deepest condolences to BIEL company and Andy’s family. I have tracked this man and his dreams since 2009 and consider him one of the greatest contributors who has led the development of advanced electroceutical devices. May the ActiPatch carry forward from your great work and place your mark as a paradigm shift visionary!
BioElectronics Newsletter
Release #:812-182889-rl-799204:
FDA Market Clearance Application Filed for Full Musculoskeletal Pain Relief
Demonstrating Significantly Superior Results to Drugs
We have filed the application with the FDA. The results demonstrate that the ActiPatch is statistically significantly superior to the prescription NAID drug in reducing neck pain.
The neck osteoarthritis study investigates the effectiveness of ActiPatch in reducing pain and satisfies the FDA requirement for a third ActiPatch study on a different musculoskeletal location to get general musculoskeletal clearance. This paves the way for new products and approved medical claims for the back, knee, muscles, joints, hips, wrists, carpal tunnel, tennis elbow, ankle sprains, Achilles tendonitis, etc.
The neck study directly compares the effectiveness of ActiPatch to that of prescription NSAID tablets. Subjects were randomly assigned either to receive the standard of care treatment, a cox-2 inhibitor (similar to Celebrex) or ActiPatch.
Clinically demonstrating a drug free superior pain relief without the dreadful side-effects of drugs is a profound monumental achievement.
Allay® Menstrual Pain Clinical Study Status
We are continuing to monitor the status of the new Allay study. We now expect that results should become available within the next 3 months. As many of you know, although our original Menstrual Pain Study had excellent results, the FDA did not accept our ad hoc Indiana University Medical School institutional review board. We trust the UK Birmingham University Hospital’s results and institutional review board will be acceptable to the UF FDA and will be publishable.
Primary dysmenorrhea (menstrual pain) is a prevalent condition among young women. 60% of 28% of the women in the menstrual phase of life (16.8%) of all women report that monthly pain and discomfort can negatively impact work productivity, cognitive performance, and quality of life.
Health Care Professionals Sales and Marketing
We are defining our US products, sales presentations, reimbursement strategy and scheduling meetings for physical therapists, orthopedic physicians, nursing homes, an orthoses and prosthetic distributor, and other health care professionals.
We are also finalizing product packaging configuration with the largest distributor of chiropractic products in US. They have access to 80% of the 70,000 chiropractors in the US who treat 35 million patients annually. ActiPatch enables the chiropractor practitioner the opportunity to prescribe take home therapy to treat sports injuries and enhance their practice.
We remain in discussions with several marketers of wraps and braces for the sports and retail markets. The next several months are key to obtain inclusion in the 2020 sales plans and shelf space. The inclusion of our ActiPatch devices gives the seller a unique advantage of being able to make specific medical claims for the treatment of pain.
US OTC Sales and Marketing Partnerships
We are in contract negotiations with a sales and marketing partner in the foot care market. We also meeting and discussing sales and marketing opportunities with several US consumer goods providers. Investor Updates August 16th, 2019
Disclosure: This newsletter is part of the bimonthly investor update; BioElectronics Corporation will be sending out this publication on the 1st and 16th (or the closest Monday) of every month. If you have further questions, please email investors@bielcorp.com.
CE Mark Renewal Status Update
Our CE Mark renewal is moving ahead and we have contracted with our Korean distributor to acquire some additional electrical testing. Now that we have ISO 13485:2016 certification for our manufacturing facility, we should be cleared for the Korean market again under the new regulations.
We continue working with the notified body (NEMKO/Presafe) to resolve the last few remaining items on the checklist required for the updated CE technical file certification. Additionally, we are working on ISO/MDSAP certification along with the technical file that comprises the two parts required to meet the updated harmonized audit requirements for Brazil, Canada, USA, Japan & Australia.
Strategy Update
Last week a shareholder sent us an email inquiring about loaning the Company money. We informed him that we do 2 year convertible notes at 8% interest and set the stock conversion price at a 50% of the closing market price on the date of investment. We also realized that while we do send out regular press releases we have not provided shareholders a recent overview of the BioElectronics development strategy.
The genesis of our technology is the continuous form of electromagnetic therapy (diathermy) which provided a method of delivering deep heat into the body with the assumption that the heat was the therapeutic agent. Pulsing the heat was done to preclude the accumulation of heat to reduce the risk of burning the patient. While there were hundreds of clinical studies, there was no adequate explanation of the mechanism of action (how does it work) for the academic community including the US FDA. We spent years looking for the answer and evidence until our VP Product Development, Dr. Sree Koneru and his mentor, Dr. Kenneth McLeod, our biophysics consultant, established through physiological testing that it was not heat but that the method of action was the pulsing. Further research established the link between pulsing and the central sensitization of pain in the nervous system, which is the new understanding of pain as a component of neurological disorders. Dr. McLeod’s video explaining the technology and central sensitization can be seen at www.actipatch.com/pharmacy/
The realization and confirmation that our device was effective therapy for neurological disorders, including pain, was our reward for our years of frustration. We now had a pathway and a mega market opportunity beyond musculoskeletal pain in migraine headaches, overactive bladder, pelvic pain, postoperative pain to mitigate opioid, use chronic wounds, etc.
Most importantly, we can grow, expand, and provide an exceptional return on investment to our investors with minimal new capital requirements. While we have spent $35 million, which is substantially more than we had originally imagined, it is still significantly less than the $120 to $260 million in development by comparative medical device companies. Additionally, our multitude of electroceuticals provides superior relief, is safer, provides a superior cost/benefit, and has broader medical applications. Investor Updates August 16th, 2019
Current Development Status
“The New Technology for Neurological Disorders” Present the Following Market Opportunities:
(Chart in Part 2)
The proper marketing and selling of medical devices requires experience management and the financial resources to sustain an adequate product introduction. Even with adequate financing it would take years to develop the management team. We are aggressively seeking qualified sales and marketing partners.
8/19/2019 8:36:45 AM
Not necessarily explosive but brick by brick things are falling in place. I am specifically speaking potential aspects of the U.S. Special Forces interest in this technology and becoming hopefully a big piece of the ActiPatch future. Nothing within the government happens quickly keep in mind but IMO there is a beginning taking place.
Actually cant relate sorry. Once began using ActiPatch many many years ago and discovered the benefits of losing the pain began my investment journey. Now its beginning to turn into something much more then I could have ever imagined! It takes time but it's almost there.
Thanks Srin, slowly coming together!
Release #:812-178187-rl-799204:
BioElectronics Files FDA Applications for Treatment of Musculoskeletal & Postoperative Pain
FREDERICK, MD, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com is pleased to announce that two Traditional 510(k) Premarket Notification applications were filed with the U.S. Food and Drug Administration (FDA). The applications were for the ActiPatch® and RecoveryRx® medical devices for market clearances of “over-the-counter adjunctive treatment of musculoskeletal pain in women”, and “over-the-counter adjunctive treatment of postoperative pain”, respectively.
The ActiPatch is already FDA-cleared for over-the-counter adjunctive treatment of pain from knee osteoarthritis (25 million Americans) and plantar fasciitis (2 million Americans annually). The medical community indicates that women are at a higher risk of developing chronic musculoskeletal pain, may experience pain more frequently and that women are more likely to use opioids for pain. The current application includes robust clinical evidence on women obtained from three clinical studies: knee osteoarthritis, plantar fasciitis and low back pain. Obtaining market clearance will position ActiPatch as a unique product that offers safe, drug-free pain relief for musculoskeletal complaints such as back, neck, hip, shoulder and carpal tunnel pain.
The RecoveryRx is currently FDA-cleared for prescription adjunctive treatment of edema following blepharoplasty (eyelid surgery). More than 15 million Americans experience postoperative pain annually. Despite existing multimodal pharmacological approaches such as NSAIDS and opioids, more than 50% of patients report severe postoperative pain. The current application includes robust clinical evidence from two studies: cesarean section and breast augmentation. Obtaining market clearance will allow RecoveryRx to enhance the effectiveness of existing multimodal therapies in reducing postoperative pain, thus reducing a patient’s risk of developing chronic postoperative pain and also reduce their exposure to long-term effects of opioid/NSAID therapy.
The 510(k) applications were prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D., Gregory Mario and Jeremy Mario, Professor, Duke University, Ian Rawe, Director of Clinical Research, BioElectronics and Sree Koneru, Ph.D., VP Product Development, BioElectronics. Dr. Koneru, who coordinated the 510(k) effort, said, “The clinical data is robust and our team has made a strong case. We look forward to a successful review of the application with the FDA.”
Keith Nalepka, VP of Sales/Marketing, expressed enthusiasm on the market opportunity: “Obtaining musculoskeletal and postoperative pain clearances will make ActiPatch and RecoveryRx devices available to more than 100 million Americans seeking safe, drug-free pain relief.”
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.tryactipatch.com.
Paul Knopick
9402623584
pknopick@eandecommunications.com
?2/12/2019 8:20:43 AM?
We have officially reached 200 registered users on https://t.co/QmvZF0ykCH, woohoo! ?????? given the rapid growth of the social network, we're now opening up advertisement opportunities. Please email contact@cbdsocialnetwork.com if interested $CBDD #CBD #cannabis
Unfortunately, the consumers don't see it that way. They have rejected ActiPatch claims.
Thank you pinhigh for your mention of credibility yes I have been here like many off and on since 2009 when Simpsonly and others were early BIELievers like me. Many of us have stayed the course and believe in the product as it has proven time after time for me in its usage. Recently a partner and myself both currently our furloughed federal government employees. Through our interfaces we have the opportunity to possibly bridge the use of the Actipatch with the U.S. Special Forces and other military applications. The term indirectly is meant in the sense that we have supplied over fifty ActiPatches to be used, demonstrated and give feedback from these government entities. So far we have had some incredible feedback for those who have used them in there respective fields. Management at BIEL has been very forth giving donating patches to our cause with and we are nearing the end of our trials with the help of Sre participating in helping us with this demonstration. As things develop I will keep the board updated and with more details.
According to New Frontier Data, “The 2018 Farm Bill will restore industrial hemp to nationwide legal production for the first time since World War II, offering vast opportunities for the industry and investment in a market expected to triple in four years.” CBDD $$$$ will be there!
Chompiee my information is not a guess. I can't discuss anything about contracts just yet especially with the government being shut down. That being said I can only validate that yes it is in the works to supply the Military/Special Forces with the patch indirectly through BIEL.
Check out our *NEW* revamped official CBD of Denver, Inc. company site (https://t.co/gkxF2RsNgi) ???? $CBDD; it will be updated with new features and better functionality real soon ??
I will one up you Tantalos and validate your comment ; )
Lets just say it has been verified the ActiPatch can be manufactured in olive green and desert storm colors. Hmmmmm, who and why would that need to be considered??? ; )
Happy Holidays to you and the board!
Exactly Tantalos! Boy I wish I could tell that individual who is in test/evaluation phase (as you know) currently evaluating the ActiPatch. Some of the feedback has just been amazing! Patience will be rewarded!
CBD of Denver is ready to take full advantage of all opportunities made possible by the Company's recent transition, and will be making additional announcements soon as we offer new products and services.
Bottom is in no better place then now to load up.
Loading up Monday! Very likely a PR.
https://www.microcapdaily.com/cbd-of-denver-inc-otcpink-cbdd-starts-trading-with-a-bang/122504/
You are absolutely correct Government now involved. Vets are only the beginning my friend! Watch what transpires in the next 6 months! ;)
Wake up? Really? I realize you have not fully researched what the government has put forth to battle the Opioid epidemic but as I said before watch, learn and listen. It will become fully evident sooner than later. ; )
Wrong, there is funding being infused to "many" parts of the Federal Government to find answers to the Opioid epidemic. I will just say BIEL is much further along than you may realize when it comes to the opioid crisis. Watch, Learn and Listen....jus sayn ;)
BioElectronics Announces Publication of Electroceuticals Article on Chronic Pain
-Revolutionizing Chronic Pain Management-
FREDERICK, MD, Oct. 04, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC Pink: BIEL), the maker of non-invasive electroceutical devices, announced the publication of an article in the October 2018 edition of the European Biopharmaceutical Review. Titled “Effective Electroceuticals,” the article provides insights into how electroceuticals (devices that provide electrical therapy) are set to revolutionize chronic pain management in the 21st century.
Chronic pain is a highly prevalent condition that affects more than 100 million Americans. Central sensitization (a.k.a. nerve hypersensitivity) is often seen as the physiological explanation for chronic pain. Existing pharmacotherapy options such as topicals, NSAID’s and opioids offer limited relief and present serious side effects with long-term use. Electroceutical devices can target central sensitization and are ideal for treating pain, but existing options (TENS etc.) require invasive or semi-invasive use and produce uncomfortable sensations. ActiPatch®, made by BioElectronics, is the only electroceutical that is non-invasive (no skin contact needed), can be used 24/7 and does not provide any uncomfortable sensations.
The article was authored by Dr. Kenneth McLeod, Ph.D., Director of the Clinical Science and Engineering Research Laboratory at the State University of New York, Binghamton and Dr. Sree Koneru, Ph.D., VP of Product Development at BioElectronics Corporation. The original article can be viewed at: http://www.bielcorp.com/EBR article .
About BioElectronics Corporation: BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses. For more information, please visit www.bielcorp.com.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
Totally agree with you Dew connect the dots with Keith's past sales history and then CVS Pharmacy/Target make perfect sense!
Mr. Nalepka has over 15 years of experience in the retail sales industry, both with large multi-million dollar brands and startups. Keith has negotiated over 500 million dollars in retail acceptance which included CVS, RA, Target and GNC.